In most people with ALS, and many with FTD, cytoplasmic aggregates of TDP-43 plague degenerating neurons. What causes an RNA-binding protein that spends most of its time in the nucleus to pile up in ...
VectorY Therapeutics Receives FDA Clearance of IND to Proceed with the PIONEER-ALS Phase 1/2 Trial of VTx-002, a First-in-Class Vectorized Antibody Targeting TDP-43 Pathology in ALS VectorY ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback